XML 50 R27.htm IDEA: XBRL DOCUMENT v3.25.0.1
Related-Party Transactions
 12 Months Ended
Dec. 31, 2024
Related Party Transactions [Abstract]  
Related-Party Transactions Related-Party Transactions
In September 2021, the Company entered into a sublease with Sonoma (“Sonoma Sublease”), with whom the Company has common stockholders with board seats, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. Dr. Klausner, the Chair of the Company’s board of directors, also serves as Board Chair of the board of directors of Sonoma. As a part of the Sonoma Sublease, a $4.6 million tenant improvement contribution payment was made by Sonoma, which is recognized over the term of the Sonoma Sublease. As of both December 31, 2024 and 2023, there were accrued liabilities and other current liabilities of $0.5 million, and as of December 31, 2024 and 2023, other non-current liabilities of $2.5 million and $3.0 million, respectively, in connection with the Sonoma Sublease. Total operating income from Sonoma and income solely attributable to the Sonoma Sublease are shown in the table below (in thousands). Total operating income includes income attributable to the sublease, as well as additional operating fees recognized in “other operating income, net” such as common area maintenance charges. See Note 11, Leases, for more detail on the Sonoma Sublease.
Year Ended December 31,
202420232022
Sonoma other operating income, net$2,838 $2,592 $2,635 
Sonoma sublease income$1,861 $1,861 $1,861 
The Company was party to the GSK Agreement, who is a holder of more than 10% of the Company’s outstanding common stock. See Note 4, License, Collaboration, and Success Payment Agreements. Revenue recognized in connection with the GSK agreement was zero for both the years ended December 31, 2024 and 2023, and $84.7 million for the year ended December 31, 2022. GSK terminated the GSK Agreement effective December 24, 2022. See Note 4, License, Collaboration, and Success Payment Agreements, for additional details regarding the termination of the GSK Agreement.